Efficacy of oral voriconazole versus itraconazole in the treatment of dermatophyte infections

Efficacy of oral voriconazole versus oral itraconazole in the treatment of dermatophyte infections

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210823052264N3

Enrollment

Registered

2023-05-19

Start date

2023-04-25

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatophyte infection. Dermatophytosis

Interventions

Intervention 1: Intervention group: In group "A" patietns were treated with Tab Voriconazole 200mg twice a day for four weeks or less in patients in which clinical response is achieved. Intervention 2

Eligibility

Sex/Gender

All

Age

15 Years to 90 Years

Inclusion criteria

Inclusion criteria: Chronic and recurrent dermatophyte infections (chronic refers to infections present for over 6 months, recurrent refers to patients with an infection in which symptoms reappear in 6 weeks after complete cure or stopping of treatment).

Exclusion criteria

Exclusion criteria: Patients with age less than 15 and greater than 90 years, Hyperlipidemia, Abnormal liver and renal function tests, Pregnant and breast feeding females.

Design outcomes

Primary

Measure	Time frame
Clinical response based on clearence of lesion and absence of fungal hyphae on KOH microscopy. Timepoint: Patients were evaluated clinically on 7th and 14th day of treatment and 4 weeks after completion of treatment. Method of measurement: Clinical evaluation.	—

Countries

Pakistan

Contacts

Public ContactDr Maira Ali

PNS Shifa

mairasmuian2012@gmail.com+92 21 48506592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026